On a magic taxi ride. Well, you don't know what we can see. Why don't you tell your dreams to me. Fantasy will set you free...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$GTBP belongs in a higher tier. So much upside here and so undervalued. I'm looking for more lucrative reveals here in the very near future, IMHO.
Dr. Ray Urbanksi is suited to this role like a hand in glove: GT Biopharma Announces Dr. Raymond W Urbanski Elevated to Chief Executive Officer and Chairman of The Board
GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP) today announced the promotion of Dr. Raymond W. Urbanski MD, PhD, to the position of Chief Executive Officer and Chairman of the Board effective immediately.
Dr. Urbanski joined the company in September 2017 as the Chief Medical Officer (CMO). He was promoted to President and CMO on May 5, 2018 in recognition for being instrumental in driving key milestones and initiatives which included being a major factor in developing a strong working relationship with the University of Minnesota, Masonic Cancer Center, the epicenter of innovation for the TriKE and TetraKE platforms, including the transitioning the first TriKE IND from the University of Minnesota to GT Biopharma while engaging the FDA in preparation for human clinical testing to begin in 2H 2018; implementing processes to expedite the identification and development of future tumor antigen targets; and driving forward our Bi-specific Antibody-Drug Conjugate platform which included the formation of our Antibody-Drug Conjugate Clinical Advisory Board.
Since that time, Dr. Urbanski has continued to push the key programs forward while implementing necessary internal processes and controls to enhance the effectiveness and efficiency of the organization.
“The platform technologies that GT Biopharma has put together from the University of Minnesota has had a major impact on me coming on board. To me, it represented cutting-edge science. We continue to advance the GT Biopharma assets, including the TriKE technology, which I view as the protein version of CAR-T. The TriKEs and TetraKEs will work not only in liquid tumors like current CAR-T therapies, but will work in solid tumors as well, which represents about 80% of patients. More importantly, this novel targeted immunotherapy will have better economics. We continue to progress these assets and I look forward to sharing with our shareholders the corporate developments that are currently happening,” said Dr. Urbanski.
Prior to joining GT Biopharma, Dr. Urbanski spent eight years with Pfizer; holding several positions of increasing responsibility with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products, and medical director of diversified products.
He has been involved in every phase of drug development and brings extensive experience in developing and overseeing clinical studies, including studies for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremelimumab.
In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
Dr. Urbanski will continue to represent the company at key international meetings such as the upcoming American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) conferences; investor conferences; and by recruiting top-tier colleagues, Scientific Advisory Board members, and consultants.
About GT Biopharma, Inc.
GT Biopharma, Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the company’s proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms. GT Biopharma’s lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GT Biopharma’s TriKE platform will address a number of cancer types. GT Biopharma’s nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma’s neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
Sometimes a management shake up is exactly what rekindles the fatih of investor land. The promise of Immunooncology has never slacked, but GTBP needed some kind of a catalyst to continue the vertical trend.
I'm counting on it. $IMTV heading to penniesville.
Once we shake off the lethargy of this holiday week and roar to life on Monday for the start of a proper business week, $IMTV should zoom deep back into green faster than you could kiss a duck.
I would go to see Juice WRLD especially if I lived closer. I think he is the next generation to inherit the hip hop /pop crossover mantle.
Concert promotion sector is a multi-billion dollar industry in the US. Not everyday a subpenny comes along that gets you access to that kind of potential revenues. $IMTV massively undervalued IMHO.
As long as the cat doesnt get the bird LMAO $IMTV
Interesting to close on a sideways move here. End of a holiday week here. This should roar back to green straight away next Monday.
Producing a Hip Hop Fest in South Miami is evidence of regional marketing strategy genius. Like promoting a southern gospel festival in Nashville. IMTV are buzz marketing gurus!
Friday should really crush it. This short week is heightening demand. $IMTV
There we go I reckoned today would see us back in green. Short week left. C'mon LIT UP Fest is just around the corner.
Yeah everyone lets ring July 4th right and punch an Englishman. ;-D
Long and strong is the way to go here. Just take a gander at the 3month chart.
Bit of a slow one today. Oh well Happy 4th to everyone! Watch for the Post Holiday $IMTV bounce.
Agreed. $1mil plus in ticket revenues seems entirely achievable. Especially now that we have upgraded to a new venue.
I wonder if we'll be gettting some updates about how the marketing campaign for LIT Up is going. It must be heating up now that we are in July.
I reckon at least $1.5 mil revs of of LIT Up. But hard to say without knowing the actual size of new venue. Either way its a great development.
I know its supposed to be an upgrade over Magic City Studios which had a 10K seating capacity.
Anal dwelling monkey? Sound about right. Those beer money day traders will get their just rewards here to. Im expecting some massive climb ups between now and LIT Up Music Festival
Dont know if I would call it "neutral". 38mil volume churned is very healthy along this vertical journey. Shaking out the punk swing traders and building in LONGs as they snatch up all these undervalued shares. Without these days we dont get the blue sky breakout days.
Yeah its fascinating how diversified the Trap genre has become in a few short years.
$1mil revenues is more like it. And I need to point out we are talking "revenues" here, not "net profit". Still a nice payday for $IMTV.
Looks like it should push deep into 24's right at open. $IMTV
But a Hobbit Full Monty? Some freak out there would buy a ticket LOL. $IMTV knows what makes the marketing game tick.
$IMTV has made a major leap forward with this partnership with NineMile Entertainment. They went from promoting classic rock/pop acts in May to promoting a lineup of current multiplatinum charttopping hip hop stars in July. This is why this wont stay under a penny for long.
Multiplatinum selling artists galore. Partnerships paying off in spades. July 28th will be sold out for sure.
Agreed, still alot of day to go and kick stirring up in IMTV.
Just when you think $IMTV might run out of steam it gets better and better. That month chart should continue the vertical trend all summer. Way too much good news and developments happening.
All of them chart toppers and A-listers. Lots of star power. $IMTV is really making the most of their partnership with Nine Mile Entertainment as far as connections to big name talent. This July 28th Miami concert will bring in immediate revs, but the connections/inroads with artists made should insure additional revs for years to come.
I imagine there would be. The XXXTentacion shooting has grabbed national headlines. It happened just across the city from the LIT Up festival venue. It would be a good chance to heal up some of the wounds in the Miami community if they used the opportunity to to memorialize XXXTentacion to an extent.
Or even by Monday power hour.
Superb close to the week for $IMTV. This week should be an even stronger round 2. Expecting to see this get pushed up right out the gate.
Hmm? whats the Jay-Z connection? Did I miss somthing?
$IMTV had a stellar week this week. This next week should really continue the trend.
YES! Great news! We are setting up for a fantastic week next week! When we get close to 5 it will be greased lightning to a penny!
Great way to approach the end of the week for $IMTV. 3 will be here soon.
YES! $IMTV back green. C'mon time to end this week strong!
Once again its shows $IMTV has a brilliant strategy with these partnerships getting them in with the hottest young stars. I agree Juice WRLD is even more interesting to me than Tekashi69 because his star is just starting to rise.